Literature DB >> 10434298

Are there multiple pathways in the pathogenesis of Huntington's disease?

N Aronin1, M Kim, G Laforet, M DiFiglia.   

Abstract

Studies of huntingtin localization in human post-mortem brain offer insights and a framework for basic experiments in the pathogenesis of Huntington's disease. In neurons of cortex and striatum, we identified changes in the cytoplasmic localization of huntingtin including a marked perinuclear accumulation of huntingtin and formation of multivesicular bodies, changes conceivably pointing to an altered handling of huntingtin in neurons. In Huntington's disease, huntingtin also accumulates in aberrant subcellular compartments such as nuclear and neuritic aggregates co-localized with ubiquitin. The site of protein aggregation is polyglutamine-dependent, both in juvenile-onset patients having more aggregates in the nucleus and in adult-onset patients presenting more neuritic aggregates. Studies in vitro reveal that the genesis of these aggregates and cell death are tied to cleavage of mutant huntingtin. However, we found that the aggregation of mutant huntingtin can be dissociated from the extent of cell death. Thus properties of mutant huntingtin more subtle than its aggregation, such as its proteolysis and protein interactions that affect vesicle trafficking and nuclear transport, might suffice to cause neurodegeneration in the striatum and cortex. We propose that mutant huntingtin engages multiple pathogenic pathways leading to neuronal death.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10434298      PMCID: PMC1692615          DOI: 10.1098/rstb.1999.0451

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  55 in total

1.  CAG expansion affects the expression of mutant Huntingtin in the Huntington's disease brain.

Authors:  N Aronin; K Chase; C Young; E Sapp; C Schwarz; N Matta; R Kornreich; B Landwehrmeyer; E Bird; M F Beal
Journal:  Neuron       Date:  1995-11       Impact factor: 17.173

2.  Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH.

Authors:  J R Burke; J J Enghild; M E Martin; Y S Jou; R M Myers; A D Roses; J M Vance; W J Strittmatter
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

3.  A huntingtin-associated protein enriched in brain with implications for pathology.

Authors:  X J Li; S H Li; A H Sharp; F C Nucifora; G Schilling; A Lanahan; P Worley; S H Snyder; C A Ross
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

4.  Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form.

Authors:  Y Trottier; D Devys; G Imbert; F Saudou; I An; Y Lutz; C Weber; Y Agid; E C Hirsch; J L Mandel
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

5.  Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models.

Authors:  C Portera-Cailliau; J C Hedreen; D L Price; V E Koliatsos
Journal:  J Neurosci       Date:  1995-05       Impact factor: 6.167

6.  Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin.

Authors:  J Bao; A H Sharp; M V Wagster; M Becher; G Schilling; C A Ross; V L Dawson; T M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

7.  SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates.

Authors:  A Sittler; S Wälter; N Wedemeyer; R Hasenbank; E Scherzinger; H Eickhoff; G P Bates; H Lehrach; E E Wanker
Journal:  Mol Cell       Date:  1998-10       Impact factor: 17.970

8.  The cortical neuritic pathology of Huntington's disease.

Authors:  M Jackson; S Gentleman; G Lennox; L Ward; T Gray; K Randall; K Morrell; J Lowe
Journal:  Neuropathol Appl Neurobiol       Date:  1995-02       Impact factor: 8.090

9.  Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies.

Authors:  C A Gutekunst; A I Levey; C J Heilman; W L Whaley; H Yi; N R Nash; H D Rees; J J Madden; S M Hersch
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

10.  Widespread expression of Huntington's disease gene (IT15) protein product.

Authors:  A H Sharp; S J Loev; G Schilling; S H Li; X J Li; J Bao; M V Wagster; J A Kotzuk; J P Steiner; A Lo
Journal:  Neuron       Date:  1995-05       Impact factor: 17.173

View more
  13 in total

1.  Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475.

Authors:  A E Rosser; R A Barker; T Harrower; C Watts; M Farrington; A K Ho; R M Burnstein; D K Menon; J H Gillard; J Pickard; S B Dunnett
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

2.  Early autophagic response in a novel knock-in model of Huntington disease.

Authors:  Mary Y Heng; Duy K Duong; Roger L Albin; Sara J Tallaksen-Greene; Jesse M Hunter; Mathieu J Lesort; Alex Osmand; Henry L Paulson; Peter J Detloff
Journal:  Hum Mol Genet       Date:  2010-07-08       Impact factor: 6.150

Review 3.  Multivesicular bodies in neurons: distribution, protein content, and trafficking functions.

Authors:  Christopher S Von Bartheld; Amy L Altick
Journal:  Prog Neurobiol       Date:  2011-01-07       Impact factor: 11.685

Review 4.  Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics.

Authors:  Anuradha Kalani; Alka Tyagi; Neetu Tyagi
Journal:  Mol Neurobiol       Date:  2013-09-03       Impact factor: 5.590

5.  Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.

Authors:  Wenzhen Duan; Qi Peng; Naoki Masuda; Eric Ford; Erik Tryggestad; Bruce Ladenheim; Ming Zhao; Jean Lud Cadet; John Wong; Christopher A Ross
Journal:  Neurobiol Dis       Date:  2008-03-10       Impact factor: 5.996

6.  Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease.

Authors:  G A Laforet; E Sapp; K Chase; C McIntyre; F M Boyce; M Campbell; B A Cadigan; L Warzecki; D A Tagle; P H Reddy; C Cepeda; C R Calvert; E S Jokel; G J Klapstein; M A Ariano; M S Levine; M DiFiglia; N Aronin
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

Review 7.  Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives.

Authors:  J J Magaña; L Velázquez-Pérez; B Cisneros
Journal:  Mol Neurobiol       Date:  2012-09-21       Impact factor: 5.590

Review 8.  Wild-type huntingtin plays a role in brain development and neuronal survival.

Authors:  Anton Reiner; Ioannis Dragatsis; Scott Zeitlin; Daniel Goldowitz
Journal:  Mol Neurobiol       Date:  2003-12       Impact factor: 5.590

9.  CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse.

Authors:  I Dragatsis; D Goldowitz; N Del Mar; Y P Deng; C A Meade; Li Liu; Z Sun; P Dietrich; J Yue; A Reiner
Journal:  Neurobiol Dis       Date:  2008-11-06       Impact factor: 5.996

Review 10.  The energetics of Huntington's disease.

Authors:  Susan E Browne; M Flint Beal
Journal:  Neurochem Res       Date:  2004-03       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.